HCW Biologics Company Insiders

HCWB Stock  USD 1.12  0.15  15.46%   
HCW Biologics employs about 36 people. The company is managed by 5 executives with a total tenure of roughly 84 years, averaging almost 16.0 years of service per executive, having 7.2 employees per reported executive. Analysis of HCW Biologics' management performance can provide insight into the company performance.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in HCW Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in producer price index.
For information on how to trade HCW Stock refer to our How to Trade HCW Stock guide.

HCW Biologics Management Team Effectiveness

The company has return on total asset (ROA) of (0.3041) % which means that it has lost $0.3041 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (277.2596) %, meaning that it created substantial loss on money invested by shareholders. HCW Biologics' management efficiency ratios could be used to measure how well HCW Biologics manages its routine affairs as well as how well it operates its assets and liabilities.
HCW Biologics secures noticeable amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares.
Some institutional investors establish a significant position in stocks such as HCW Biologics in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of HCW Biologics, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

HCW Biologics Workforce Comparison

HCW Biologics is rated # 2 in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 175. HCW Biologics totals roughly 36.0 in number of employees claiming about 21% of equities under Health Care industry.

HCW Biologics Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific HCW Biologics insiders, such as employees or executives, is commonly permitted as long as it does not rely on HCW Biologics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, HCW Biologics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

HCW Biologics Notable Stakeholders

A HCW Biologics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as HCW Biologics often face trade-offs trying to please all of them. HCW Biologics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting HCW Biologics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Raquel MSDirector ResourcesProfile
Hing WongCEO, FounderProfile
Lee FlowersSenior DevelopmentProfile
Peter RhodeChief OperationsProfile
Nicole EsqVice AffairsProfile
String symbol = request.getParameter("s");

About HCW Biologics Management Performance

The success or failure of an entity such as HCW Biologics often depends on how effective the management is. HCW Biologics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of HCW management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the HCW management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company was incorporated in 2018 and is headquartered in Miramar, Florida. Hcw Biologics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 44 people.
Please note, the presentation of HCW Biologics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, HCW Biologics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of HCW Biologics' management manipulating its earnings.

HCW Biologics Workforce Analysis

Traditionally, organizations such as HCW Biologics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare HCW Biologics within its industry.

HCW Biologics Manpower Efficiency

Return on HCW Biologics Manpower

Revenue Per Employee71.3K
Revenue Per Executive513.4K
Net Loss Per Employee834K
Net Loss Per Executive6M

Complementary Tools for HCW Stock analysis

When running HCW Biologics' price analysis, check to measure HCW Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy HCW Biologics is operating at the current time. Most of HCW Biologics' value examination focuses on studying past and present price action to predict the probability of HCW Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move HCW Biologics' price. Additionally, you may evaluate how the addition of HCW Biologics to your portfolios can decrease your overall portfolio volatility.
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Equity Valuation
Check real value of public entities based on technical and fundamental data
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets